Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer

Table 3

Univariate analysis and multivariate analysis of progression-free time.

Variable category	Category	Univariate analysis		Multivariate analysis
		HR (95% CI)	value	HR (95% CI)	value
Gender	Female versus male	0.97 (0.64-1.47)	0.894	0.92 (0.556-1.533)	0.757
Age	⩾59 versus <59	1.29 (0.88-1.88)	0.182	1.33 (0.83-2.11)	0.236
ECOG	⩾2 versus 0-1	1.96 (1.14-3.37)	0.012	2.74 (1.52-4.96)	0.001
Tumor_location	Cardia versus body/fundus versus pylorus	0.89 (0.70-1.10)	0.114	1.07 (0.81-1.40)	0.636
Histological_differentiation	Poorly versus moderately and well	1.44 (0.99-2.08)	0.051	1.54 (1.00-2.37)	0.049
No. of metastasis organs	≥2 versus <2	1.40 (0.91-2.17)	0.119	1.24 (0.78-1.97)	0.370
Liver metastasis	Yes versus no	0.99 (0.68-1.45)	0.966	0.96 (0.61-1.49)	0.847
Smoking_history	Smoke versus never smoked	1.39 (0.97-2.02)	0.072	1.37 (0.83-2.27)	0.223
Drinking_history	Drink versus never drinked	0.84 (0.58-1.22)	0.361	0.95 (0.57-1.58)	0.830
Anti-PD-1 therapy line	First line versus second line and third line	0.61 (0.43-0.89)	0.008	0.65 (0.41-1.04)	0.074
Treatment type	Anti-PD-1 plus chemotherapy versus anti-PD-1 monotherapy or antiangiogenesis	0.67 (0.45-0.94)	0.033	1.12 (0.68-1.87)	0.647
Baseline NLR	<3.23 versus ≥3.23	0.42 (0.29-0.62)	<0.001	0.43 (0.29-0.64)	<0.001

CI: confidence interval; ECOG PS: Eastern Cooperative Oncology Group Performance Status; NLR: neutrophil-to-lymphocyte ratio; HR: hazard ratio.